Effect of TU-100 in Patients With Functional Constipation
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the improvement in the severity of
constipation (from Baseline to Day 28), determined by the constipation severity instrument
(CSI) score [1], compared to placebo, following a total daily oral dose of 15 g TU-100
administered for 28 consecutive days in adult subjects with functional constipation.